US Patent

US10159683 — Use of sustained release dexamethasone in post-cataract surgery inflammation

Formulation · Assigned to Icon Bioscience Inc · Expires 2034-05-23 · 8y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a short-term sustained release liquid formulation of dexamethasone in citrate for anti-inflammatory therapy after cataract surgery.

USPTO Abstract

The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.

Drugs covered by this patent

Patent Metadata

Patent number
US10159683
Jurisdiction
US
Classification
Formulation
Expires
2034-05-23
Drug substance claim
No
Drug product claim
Yes
Assignee
Icon Bioscience Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.